Compare PLUR & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUR | RDI |
|---|---|---|
| Founded | 2001 | 1937 |
| Country | Israel | United States |
| Employees | N/A | 2005 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 23.4M |
| IPO Year | 2001 | N/A |
| Metric | PLUR | RDI |
|---|---|---|
| Price | $2.09 | $1.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 19.2K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,336,000.00 | N/A |
| Revenue This Year | $97.38 | $16.25 |
| Revenue Next Year | $293.97 | $4.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 309.82 | N/A |
| 52 Week Low | $1.99 | $0.94 |
| 52 Week High | $5.96 | $1.65 |
| Indicator | PLUR | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 56.24 |
| Support Level | N/A | $0.99 |
| Resistance Level | $2.58 | $1.29 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 22.73 | 55.56 |
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.